Establishment of a rat osteoporotic model by ovariectomy combined with glucocorticoid exposure

doi:10.3969/j.issn.2095-4344.2017.24.015

Abstract

Abstract:

BACKGROUND: There are many postmenopausal women taking hormone, which leads to much loss of bone mass, further inducing fragility fractures. The studies on the hormone exposure combined with ovariectomy-induced osteoporotic model are still immature, and the related molecular mechanism remains unclear.
OBJECTIVE: To establish the rat osteoporotic model induced by ovariectomy combined with glucocorticoid exposure and to explore the underlying molecular mechanism.
METHODS: Thirty 3-month-old female Sprague-Dawley rats were randomly divided into blank control, sham and model groups (n=10 per group). The rats in the blank control group received no intervention; rats in the sham group were clipped off a little of coeliac adipose tissue; the model rats received bilateral ovariectomy and 4-week administration of glucocorticoid.
RESULTS AND CONCLUSION: At 4 weeks after modeling, compared with blank control and sham groups, the model group showed significantly lower bone mineral density of the femur, number of bone trabeculae and bone volume/total volume, and significantly wider bone trabecular spacing. Additionally, the model group revealed the damaged bone trabecular structure and thiner cortical bone. The expression level of Runx2 was downregulated whereas both collagen type 1 α1 and peroxisome proliferators activated receptor γ mRNA were upregulated in the model group. These findings suggest that ovariectomized rats exposed to glucocorticoid rapidly develop femur osteoporosis, maybe by downregulating the expression of Runx2, as well as upregualting collagen type 1 α1 and peroxisome proliferators activated receptor γ mRNA.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Osteoporosis, Dexamethasone, Ovary, Tissue Engineering

CLC Number:

R318

Zhang Yu-zhuo, Shen Geng-yang, Zhang Zhi-da, Zhao Wen-hua, Huang Jin-jing, Yu Xiang, Qiu Ting, Lu Yong-qiang, Zhan Mei-qi, Yang Zhi-dong, Yao Zhen-song, Liang De. Establishment of a rat osteoporotic model by ovariectomy combined with glucocorticoid exposure[J]. Chinese Journal of Tissue Engineering Research, 2017, 21(24): 3858-3863.

Figures/Tables 3

References

[1] Wang J, Wang Y, Liu WD, et al. Hip fractures in Hefei, China: the Hefei osteoporosis project. J Bone Miner Metab. 2014; 32(2):206-214.

[2] 黄燕兴,朱弼堃,张红.髋部骨折住院治疗费用统计和分析(1998-2003年)[J].中国骨质疏松杂志,2005,11(2):195-198.

[3] 刘媛,王永福,刘忠厚.糖皮质激素和骨质疏松关系的研究进展[J].中国骨质疏松杂志,2010,16(9):713-718.

[4] Baccaro LF, Conde DM, Costa-Paiva L, et al. The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil. Clin Interv Aging. 2015;10:583-591.

[5] Whittier X, Saag KG. Glucocorticoid-induced Osteoporosis. Rheum Dis Clin North Am. 2016;42(1):177-189, x.

[6] Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62(11): 1515-1526.

[7] Overman RA, Toliver JC, Yeh JY, et al. United States adults meeting 2010 American College of Rheumatology criteria for treatment and prevention of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2014;66(11): 1644-1652.

[8] 张智海,刘忠厚,李娜,等.中国人骨质疏松症诊断标准专家共识(第三稿•2014版)[J].中国骨质疏松杂志,2014,20(9):1007-1010.

[9] 郭鱼波,马如风,王丽丽,等.骨质疏松动物模型及其评价方法的研究进展[J].中国骨质疏松杂志,2015,21(9):1149-1154.

[10] 张春丽,李忠海,周颖,等.构建骨质疏松动物模型建模方法的改进及评价[J].中国组织工程研究,2016,20(5):754-759.

[11] Kalpakcioglu BB, Engelke K, Genant HK. Advanced imaging assessment of bone fragility in glucocorticoid-induced osteoporosis. Bone. 2011;48(6):1221-1231.

[12] Wu WJ, Lee HY, Lee GH, et al. The antiosteoporotic effects of Cheonggukjang containing vitamin k2 (menaquinone-7) in ovariectomized rats. J Med Food. 2014;17(12):1298-1305.

[13] Govindarajan P, Khassawna T, Kampschulte M, et al. Implications of combined ovariectomy and glucocorticoid (dexamethasone) treatment on mineral, microarchitectural, biomechanical and matrix properties of rat bone. Int J Exp Pathol. 2013;94(6):387-398.

[14] Böcker W, El Khassawna T, Bauer N, et al. Short-term glucocorticoid treatment causes spinal osteoporosis in ovariectomized rats. Eur Spine J. 2014;23(11):2437-2448.

[15] Baofeng L, Zhi Y, Bei C, et al. Characterization of a rabbit osteoporosis model induced by ovariectomy and glucocorticoid. Acta Orthop. 2010;81(3):396-401.

[16] Jackson RD, Mysiw WJ. Insights into the epidemiology of postmenopausal osteoporosis: the Women's Health Initiative. Semin Reprod Med. 2014;32(6):454-462.

[17] Liu X, Lei W, Wu Z, et al. Effects of glucocorticoid on BMD, micro-architecture and biomechanics of cancellous and cortical bone mass in OVX rabbits. Med Eng Phys. 2012; 34(1):2-8.

[18] 段瑞平,吴凌,林云锋,等.不同成骨诱导作用下骨髓间充质干细胞的基因表达模式[J].四川大学学报(医学版),2006,37(6): 856-859.

[19] 代志鹏,许伟华,杨述华,等.人骨髓间充质干细胞的生物学特性及成骨诱导分化的研究[J].中国矫形外科杂志,2014,22(15): 1402-1407.

[20] 余炜,朱超,茅伟伟,等.神经肽P物质通过诱导RUNX2表达对小鼠成骨细胞增殖能力的影响[J].上海交通大学学报(医学版),2017, 37(1):15-20.

[21] 唐欢,许海甲,侯煜东,等.Runx2基因对骨代谢调控的研究进展[J].中国骨质疏松杂志,2014,20(12):1501-1505.

[22] Martin A, Xiong J, Koromila T, et al. Estrogens antagonize RUNX2-mediated osteoblast-driven osteoclastogenesis through regulating RANKL membrane association. Bone. 2015;75:96-104.

[23] 宋纯理,党耕町.髓腔内脂肪细胞与骨质疏松[J].中国骨质疏松杂志,2002,8(3):266-269.

[24] Ding ST, Schinckel AP, Weber TE, et al. Expression of porcine transcription factors and genes related to fatty acid metabolism in different tissues and genetic populations. J Anim Sci. 2000;78(8):2127-2134.

[25] 黄成校,余化龙,高超,等.骨髓间充质干细胞复合Ⅰ型胶原修饰的聚乳酸聚乙醇酸对骨质疏松大鼠骨缺损的影响[J].安徽医药, 2017,21(4):618-622.

[26] Kurt-Sirin O, Yilmaz-Aydogan H, Uyar M, et al. Combined effects of collagen type I alpha1 (COL1A1) Sp1 polymorphism and osteoporosis risk factors on bone mineral density in Turkish postmenopausal women. Gene. 2014;540(2): 226-231.

[27] 宗强,李立军,姜竹岩, 等.Ⅰ型胶原α1 Sp1多态性与骨密度和骨折关联性的Meta分析[J].中国组织工程研究,2015,19(33): 5395-5401.

[28] 何进卫,章振林.上海绝经后妇女Ⅰ型胶原α1基因多态性与骨密度关系的研究[J].中国全科医学,2007,10(7):531-532,535.

[29] Hu M, Ou-Yang HF, Wu CG, et al. Notch signaling regulates col1α1 and col1α2 expression in airway fibroblasts. Exp Biol Med (Maywood). 2014;239(12):1589-1596.

[30] Wang ZF, Guo X, Bai GL, et al. Detection of serum PICP and PINP and COL1alpha1 DNA sequence analysis in patients with arsenic poisoning in Dazhuyuan Town, Ankang area in southern Shaanxi Province. Nan Fang Yi Ke Da Xue Xue Bao. 2008;28(7):1141-1144.

[31] Liu S, Liao G, Li G. Regulatory effects of COL1A1 on apoptosis induced by radiation in cervical cancer cells. Cancer Cell Int. 2017;17:73.

[32] Seto T, Yamamoto T, Shimojima K, et al. A novel COL1A1 mutation in a family with osteogenesis imperfecta associated with phenotypic variabilities. Hum Genome Var. 2017;4: 17007.

[33] Ackermann AM, Levine MA. Compound heterozygous mutations in COL1A1 associated with an atypical form of type I osteogenesis imperfecta. Am J Med Genet A. 2017. in press.

[34] Andersson K, Dahllöf G, Lindahl K, et al. Mutations in COL1A1 and COL1A2 and dental aberrations in children and adolescents with osteogenesis imperfecta - A retrospective cohort study. PLoS One. 2017;12(5):e0176466.

[35] Legendre F, Ollitrault D, Gomez-Leduc T, et al. Enhanced chondrogenesis of bone marrow-derived stem cells by using a combinatory cell therapy strategy with BMP-2/TGF-β1, hypoxia, and COL1A1/HtrA1 siRNAs. Sci Rep. 2017;7(1): 3406.

[36] Lee JS, Seo J, Cho A, et al. Severe hypotonia and postnatal growth impairment in a girl with a missense mutation in COL1A1: Implication of expanded phenotypic spectrum of type I collagenopathy. Brain Dev. 2017. in press.

[37] Bai GP, Yan GH, Wang GJ, et al. Effects of lentiviral vector?mediated shRNA silencing of TGFβ1 on the expression of Col1a1 in rat hepatic stellate cells. Mol Med Rep. 2017;16(3): 2785-2790.

[38] Selinger CI, Day CJ, Morrison NA. Optimized transfection of diced siRNA into mature primary human osteoclasts: inhibition of cathepsin K mediated bone resorption by siRNA. J Cell Biochem. 2005;96(5):996-1002.

[39] Wilson SR, Peters C, Saftig P, et al. Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption. J Biol Chem. 2009;284(4): 2584-2592.

[40] Kozloff KM, Quinti L, Tung C, et al. Non-invasive imaging of osteoclast activity via near-infrared cathepsin-K activatable optical probe. J Musculoskelet Neuronal Interact. 2006; 6(4):353.

[41] Chen W, Yang S, Abe Y, et al. Novel pycnodysostosis mouse model uncovers cathepsin K function as a potential regulator of osteoclast apoptosis and senescence. Hum Mol Genet. 2007;16(4):410-423.

[42] Kozloff KM, Quinti L, Patntirapong S, et al. Non-invasive optical detection of cathepsin K-mediated fluorescence reveals osteoclast activity in vitro and in vivo. Bone. 2009; 44(2):190-198.

[43] Motyckova G, Fisher DE. Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease. Curr Mol Med. 2002;2(5):407-421.

[44] Kim MK, Kim HD, Park JH, et al. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats. J Pharmacol Exp Ther. 2006;318(2):555-562.

[45] 王东,顾建红,刘宗平.组织蛋白酶K在骨吸收中的作用研究进展[J].动物医学进展,2014,35(6):114-116.

[46] Zhou J, Li X, Liao Y, et al. Effects of electroacupuncture on bone mass and cathepsin K expression in ovariectomised rats. Acupunct Med. 2014;32(6):478-485.

[47] Jacome-Galarza C, Soung do Y, Adapala NS, et al. Altered hematopoietic stem cell and osteoclast precursor frequency in cathepsin K null mice. J Cell Biochem. 2014;115(8): 1449-1457.

[48] Siddiqi MH, Siddiqi MZ, Kang S, et al. Inhibition of Osteoclast Differentiation by Ginsenoside Rg3 in RAW264.7 Cells via RANKL, JNK and p38 MAPK Pathways Through a Modulation of Cathepsin K: An In Silico and In Vitro Study. Phytother Res. 2015. in press.

[49] Ren ZY, Machuca-Gayet I, Domenget C, et al. Azanitrile Cathepsin K Inhibitors: Effects on Cell Toxicity, Osteoblast-Induced Mineralization and Osteoclast-Mediated Bone Resorption. PLoS One. 2015;10(7):e0132513.

[50] Wilson S, Hashamiyan S, Clarke L, et al. Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities. Am J Pathol. 2009;175(5): 2053-2062.

[51] Lotinun S, Kiviranta R, Matsubara T, et al. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest. 2013;123(2):666-681.

[52] Aumiller J. Cathepsin K inhibitor: new therapy approach against osteoporosis. Pharmacological target in the osteoclast. MMW Fortschr Med. 2011;153(19):16.